Metabolic features of cancer cells in NRF2 addiction status

Keito Okazaki1, Thales Papagiannakopoulos2, Hozumi Motohashi3

  • 1Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University, Sendai, 980-8575, Japan.

Biophysical Reviews
|March 1, 2020
PubMed

Insights

The KEAP1-NRF2 system regulates cellular defense against stress. In cancers, this system

Area of Science:

  • Cellular Biology
  • Biochemistry
  • Oncology

Background:

  • The Kelch-like ECH-associated protein 1 (KEAP1)-Nuclear factor erythroid 2-related factor 2 (NRF2) pathway is crucial for cellular defense against oxidative and electrophilic stress.
  • KEAP1 normally inhibits NRF2, a transcription factor that activates genes involved in redox reactions.
  • Dysregulation of the KEAP1-NRF2 pathway leads to persistent NRF2 activation, a state known as NRF2 addiction in cancer cells.

Purpose of the Study:

  • To investigate the metabolic consequences of NRF2 addiction in cancer cells.
  • To elucidate how persistent NRF2 activation drives malignant progression and therapeutic resistance.
  • To identify novel therapeutic strategies targeting NRF2-addicted cancers based on their metabolic vulnerabilities.

Main Methods:

  • Analysis of gene expression patterns related to NRF2 targets.
  • Metabolic flux analysis in cancer cells with varying NRF2 activity.
  • Investigation of amino acid and glutathione metabolism.
  • Assessment of TCA cycle anaplerosis and mitochondrial respiration.

Main Results:

  • NRF2 addiction promotes metabolic reprogramming, including enhanced cystine uptake and glutathione synthesis.
  • This leads to increased glutamate consumption, limiting TCA cycle anaplerosis and mitochondrial respiration.
  • Cancer cells become dependent on exogenous non-essential amino acids.
  • Altered sulfur metabolism supports antioxidant capacity at the expense of central carbon metabolism.

Conclusions:

  • NRF2 addiction creates specific metabolic dependencies in cancer cells.
  • Targeting these metabolic vulnerabilities offers a promising therapeutic strategy for NRF2-addicted cancers.
  • Understanding the metabolic rewiring driven by NRF2 is key to developing effective cancer treatments.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K